ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
- Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/16/2025
|
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
- WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced confirmation of alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel. Rilparencel is an autologous cellular therapy that received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and currently is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy's potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
- 07/15/2025
|
Live Nasdaq Composite: Markets Attempt Gains on Renewed Trade Deal Bets
- Live Updates Live Coverage Has Ended X Executive Shakeup 1:06 pm by Gerelyn Terzo Uncertainty has gripped yet another one of Elon Musk’s companies after X CEO Linda Yaccarino revealed she would be stepping down. Yaccarino has led the social media platform for the past two years amid a mandate to draw advertisers back after Musk’s high-profile takeover. Musk’s other company, Tesla (Nasdaq: TSLA), has been under fire as investors punish the stock for the tech innovator’s political ambitions. The markets are holding their gains today, with the Nasdaq Composite now up 0.61%. Nvidia Crosses $4 Trillion Market Cap 10:50 am by Gerelyn Terzo Nvidia stock has crossed the $4 trillion market cap, making it the first company in history to reach this massive size. The stock is currently up 1.6% to hover at $162.63 per share after rising as high as $164.42 intraday to put it over the top. Nvidia first clinched the $3 trillion market cap level last year. Wall Street Moves 9:53 am by Gerelyn Terzo Morgan Stanley has reiterated its “overweight” rating on Apple (Nasdaq: AAPL) stock, saying the company will experience minimal disruption amid the departure of a C-Suite executive. RBC analysts have reiterated their “outperform” rating on Elon Musk’s Tesla (Nasdaq: TSLA), touting the EV maker’s Q2 deliveries. Goldman Sachs has lowered its rating on shares of SolarEdge (Nasdaq: SEDG), owing to a cloud of regulatory uncertainty around the broader solar sector. This article will be updated throughout the day, so check back often for more daily updates. The markets are seeing signs of optimism for trade-deal progress, sending stocks higher across the board out of the gate. On the technology front, Nvidia (Nasdaq; NVDA) is up 2%, inching closer to the coveted $4 trillion market cap level. On trade, President Trump is targeting specific sectors of the economy, including a 50% tariff on copper imports, sending the price of metal to all-time highs this week. Copper, which is in demand amid the transition to clean energy, soared by 17% to its biggest one-day gain in decades. Sectors of the economy are trading mixed with energy stocks out front, posting a 2.7% gain as a group. Apple (Nasdaq: AAPL) is trading relatively flat after a White House trade official has said that the iPhone maker believes it’s ‘too big to tariff.’ Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Up 206.77 (+0.48%) Nasdaq Composite: Up 156.50 (+0.74%) S&P 500: Up 32.35 (+0.52%) Market Movers Credit company Fair Isaac (NYSE: FICO), better known as FICO, is under pressure after the Trump administration greenlighted an alternative credit formula, paving the way for more renters to become homeowners and achieve the American Dream. Digital healthcare platform Hims & Hers (NYSE: HIMS) is rising 1.1% as investors cheer the company’s plans to expand its North American footprint into Canada. Healthcare stock ProKidney (Nasdaq: PROK), with a market cap of $2.8 billion, is rallying 53.6% today. The post Live Nasdaq Composite: Markets Attempt Gains on Renewed Trade Deal Bets appeared first on 24/7 Wall St..
- 07/10/2025
|
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
- Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
- 07/09/2025
|
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
- Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.
- 07/09/2025
|
ProKidney: What's Happening With PROK Stock?
- ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from chronic kidney disease (CKD) and diabetes. The study indicated considerable enhancements in kidney function:
- 07/09/2025
|
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
- WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:
- 07/09/2025
|
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
- ProKidney (PROK 513.36%) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.
- 07/08/2025
|
ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying
- The stock of the day on Tuesday was ProKidney Corp.'s, as it was both the biggest gainer and the most actively traded on major U.S. exchanges, after the biotechnology company's diabetes treatment produced positive results in a mid-stage trial.
- 07/08/2025
|
Gold Falls 1%; ProKidney Shares Spike Higher
- U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.
- 07/08/2025
|
Why Is Penny Stock ProKidney Trading Higher On Tuesday?
- ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.
- 07/08/2025
|
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
- WINSTON-SALEM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial evaluating rilparencel in patients with CKD and diabetes. Rilparencel is an autologous cellular therapy that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food & Drug Administration (FDA) and is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy's potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
- 07/08/2025
|
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
- WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and (ii) each Class B ordinary share automatically converted into one share of Class B common stock of ProKidney. ProKidney common stock will begin trading on July 2, 2025, and the Company's trading symbol on the Nasdaq Stock Market will remain unchanged as "PROK." The Company's CUSIP number relating to its Class A common stock changed to 74291D 104. The Company does not anticipate any impact to day-to-day business operations as a result of the domestication.
- 07/01/2025
|
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
- WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results and business highlights for the first quarter ended March 31, 2025.
- 05/12/2025
|
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
- PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 03/21/2025
|
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
- WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results and business highlights for the year ended December 31, 2024.
- 03/17/2025
|
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm
- NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
- 01/31/2025
|
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
- Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that's suitable for the FDA.
- 01/31/2025
|
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
- WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
- 11/26/2024
|
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
- WINSTON-SALEM, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2024, and gave several regulatory and clinical development updates.
- 11/12/2024
|
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
- WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November.
- 11/05/2024
|
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024
- WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.
- 10/14/2024
|
ProKidney to Participate in the UBS Virtual Organ Restoration Day
- WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024.
- 10/09/2024
|
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.
- WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced CKD.
- 09/03/2024
|
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024.
- 08/27/2024
|
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
- WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the second quarter ended June 30, 2024.
- 08/09/2024
|
Play Likely Earnings Beat With 3 Top-Ranked Stocks
- Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.
- 06/21/2024
|
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
- WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct offering is not contingent on the closing of the underwritten public offering.
- 06/11/2024
|
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
- WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company.
- 06/10/2024
|
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
- WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates. Management will host a live webcast today at 8:00 a.m. ET to discuss the data.
- 06/10/2024
|
ProKidney to Participate in the Jefferies Global Healthcare Conference
- WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY.
- 05/29/2024
|
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
- WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe CKD caused by diabetes as well as the importance of preserving kidney function in this patient population. To register, click here .
- 05/21/2024
|
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
- WINSTON-SALEM, N.C., May 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the first quarter ended March 31, 2024.
- 05/10/2024
|
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
- Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies
- 03/25/2024
|
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.
- 03/21/2024
|
ProKidney to Participate in Jefferies Biotech on the Bay Summit
- WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024.
- 02/29/2024
|
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
- ProKidney Corp. (PROK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 12/13/2023
|
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
- Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney
- 11/30/2023
|
7 Penny Stocks With Low Floats and High Short Interest
- There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
- 11/24/2023
|
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
- WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients living with chronic kidney disease (CKD), today announced that management will be participating in a fireside chat at the 6th Annual Evercore ISI HEALTHCONx Conference being held in Miami, Florida on November 28-30, 2023.
- 11/21/2023
|
ProKidney Corp. (PROK) Q3 2023 Earnings Call Transcript
- ProKidney Corp. (NASDAQ:PROK ) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET Company Participants Dr. Glenn Schulman - SVP of IR Pablo Legorreta - Chairman of Board Dr. Tim Bertram - Co-Founder and Member of Scientific Advisory Board Dr. Bruce Culleton - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi Justin Zelin - BTIG Jonathan Miller - Evercore Jason Gerberry - Bank of America Operator Good morning, ladies and gentlemen, and welcome to the ProKidney Corporate Update Conference Call. At this time, all lines are in a listen-only mode.
- 11/16/2023
|
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
- The heavy selling pressure might have exhausted for ProKidney Corp. (PROK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 11/16/2023
|
ProKidney Reports Third Quarter Financial Results
- WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023.
- 11/14/2023
|
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
- Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients
- 11/13/2023
|
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023
- Total of 6 abstracts accepted for publication in Kidney Week 2023 program Total of 6 abstracts accepted for publication in Kidney Week 2023 program
- 10/30/2023
|
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- ProKidney Corp. (PROK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 10/17/2023
|
Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?
- Shares of ProKidney (NASDAQ: PROK ) are in the green today, despite recent sales from special purpose acquisition company (SPAC) sponsor Chamath Palihapitiya. Back in July of 2022, ProKidney agreed to merge with Social Capital Suvretta Holdings Corp III in a business combination valued at $2.64 billion.
- 10/16/2023
|
Why Shares of ProKidney Were Dropping Thursday
- ProKidney focuses on therapies to treat chronic kidney disease (CKD). One of its top shareholders sold roughly $1.23 million worth of company stock.
- 10/12/2023
|
Short squeeze alert for September 27th: 2 stocks that could skyrocket
- Stock market investors are regularly monitoring highly shorted stocks, as the potential for an abrupt surge looms large.
- 09/27/2023
|
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
- WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, being held in New York, NY from September 11 – 14, 2023.
- 09/05/2023
|
Short squeeze alert for September 4th: Two stocks with potential to skyrocket
- A short squeeze is when traders who heavily short a stock start to cover their short positions by buying back the stock. This increases demand for the stock, and it pushes the price higher, forcing other short sellers to buy back.
- 09/04/2023
|
3 Biotech Stocks Due for a Massive Short Squeeze
- Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.
- 08/31/2023
|
ProKidney to Present at the BofA Securities Health Care Conference 2023
- WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the BofA Securities Health Care Conference 2023 in Las Vegas, NV on Tuesday, May 9, 2023, at 4:20 PM PDT (7:20 PM EDT).
- 05/04/2023
|
ProKidney: Too Many Billionaires, Too Little Data
- ProKidney Corp. has a noble goal - ending kidney dysfunction using cell therapy. It has produced some interesting data from a phase 2 trial.
- 04/12/2023
|
ProKidney's stock jumps 29%
- Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company's investigational renal autologous cell therapy treatment can delay the need for dialysis in some patients with chronic kidney disease. The study was published Jan. 4 in the journal Blood Purification; the company issued a news release about the study on Tuesday.
- 01/11/2023
|
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
- WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Wednesday, January 11th, 2023, at 3:45 PM PT.
- 12/22/2022
|
ProKidney to Participate in Upcoming Investor Conferences
- WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in the following upcoming investor conferences:
- 11/11/2022
|
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
- WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.
- 09/23/2022
|
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
- WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will participate in a fireside chat on Wednesday, September 14, 2022, at the Morgan Stanley 20 th Annual Global Healthcare Conference, in New York, NY. During the fireside chat, ProKidney plans to discuss its commercialization strategies and potential line extensions to expand market access, approaches to drive down cost of goods, and scaling of manufacturing to meet future market demand.
- 09/08/2022
|
ProKidney to present at upcoming investor conferences
- WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced that Tim Bertram, PhD, Chief Executive Officer, will present at the following investor conferences:
- 05/20/2022
|
ProKidney to Present REACT® at 4th Annual CKD Summit
- WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced that Joseph Stavas, MD, MPH, Senior Vice President of Clinical Development, will present data on the Company's lead product candiate, Renal Autologous Cell Therapy (REACT®) at the 4th Annual CKD Summit, being held March 1-3, 2022 in Boston, MA.
- 03/01/2022
|
ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)
- ProKidney entered into a definitive agreement to become a publicly-traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). These are the details.
- 01/18/2022
|
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
- ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III (NASDAQ: DNAC) in a deal valuing the combined entity at $2.64 billion. ProKidney first made waves in 2019, when it disclosed the $62 million acquisition of inRegen and raised $75 million to fund the deal and another takeover.
- 01/18/2022
|
ProKidney set to go public after SPAC merger that values combined company at $2.6 billion
- ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC, +0.19% in a deal that values the combined company at $2.64 billion. The deal, which will take ProKidney public, is expected to provide $825 million in cash proceeds.
- 01/18/2022
|
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
- The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space.
- 01/09/2022
|
